Expert Interview
Discussing DURECT Corporation's Announcement of Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis.
Ticker(s): DRRXInstitution: Rutgers University
- Board Certified in Gastroenterology and Internal Medicine
- Distinguished professor of medicine, Director of Hepatology, Professor of Epidemiology, Pathology & and Lab medicine at RU
- Interests include Viral hepatitis, End-stage liver disease, Hepatocellular carcinoma, Fatty liver disease, Autoimmune liver disease, Management of post-liver transplant patients
- Manages 800 individual patients with alcohol-associated hepatitis
Describe your background and practice setting
Added By: nick_adminHow many patients with AlcHep do you currently manage?
Added By: nick_adminCan you describe the standard of care for AlcHep?
Added By: nick_adminWhere will Larsucosterol fit into your treatment algorithm for AlcHep?
Added By: nick_adminRank your excitement for Larsucosterol on a scale of 1-10
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
